Search - tctmd.com

Displaying 101 - 120 of 149

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for July 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2020

July 31, 2020

TCTMD’s Top 10 Most Popular Stories for June 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2020

July 02, 2020

Good Results With Next-Gen, Self-Expanding TAVR in Bicuspid Valves

News Daily News

Good Results With Next-Gen, Self-Expanding TAVR in Bicuspid Valves

Michael O'Riordan

May 27, 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

News Conference News HRS 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

May 15, 2020

Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance

News Features

Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance

April 29, 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

In-Hospital Complications, Mortality High With Lead Extractions for Device Infections

News Daily News

In-Hospital Complications, Mortality High With Lead Extractions for Device Infections

November 06, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

AMBULATE: Venous Closure Device Pays Off After Catheter Ablation

News Daily News

AMBULATE: Venous Closure Device Pays Off After Catheter Ablation

October 31, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Safe to Leave Recalled Sprint Fidelis ICD Leads in Place? Debate Continues

News Daily News

Safe to Leave Recalled Sprint Fidelis ICD Leads in Place? Debate Continues

August 28, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

News Conference News EuroPCR 2019

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

Michael O'Riordan

May 22, 2019

PRAGUE-12: Surgical Ablation of A-fib During Cardiac Surgery Has Long-term Stroke Benefit

News Conference News HRS 2019

PRAGUE-12: Surgical Ablation of A-fib During Cardiac Surgery Has Long-term Stroke Benefit

May 20, 2019

News Industry News

Biosense Webster Announces Initial Results From First In-Human Study Of Novel High Power-Short Duration Ablation Catheter For Atrial Fibrillation

May 09, 2019

News Industry News

Intelligent Data Analytics Software Solution Comes To Electrophysiology With Launch Of Biosense Webster’s Cartonet

May 07, 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

March 11, 2019

News Industry News

First Atrial Fibrillation Patient Treated In Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter

February 04, 2019

New-Onset A-fib Following Noncardiac Surgery: Beware the Thromboembolic Risk

News Daily News

New-Onset A-fib Following Noncardiac Surgery: Beware the Thromboembolic Risk

Yael L. Maxwell

October 16, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.